Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

被引：6

作者：

van Nes, J. G. H. ^{[1
]}

Seynaeve, C. ^{[2
]}

Maartense, E. ^{[3
]}

Roumen, R. M. H. ^{[4
]}

de Jong, R. S. ^{[5
]}

Beex, L. V. A. M. ^{[6
]}

Kranenbarg, W. M. Meershoek-Klein ^{[7
]}

Putter, H. ^{[8
]}

Nortier, J. W. R. ^{[9
]}

van de Velde, C. J. H. ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands

[2] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands

[3] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands

[4] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands

[5] Martini Hosp, Dept Internal Med, Groningen, Netherlands

[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands

[7] Leiden Univ, Med Ctr, Datactr Surg, NL-2300 RC Leiden, Netherlands

[8] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands

[9] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 05期

关键词：

breast cancer; endocrine therapy; guideline; patterns of care; AROMATASE INHIBITORS; THERAPY; WOMEN; SURVIVAL; RECOMMENDATIONS; NETHERLANDS; MASTECTOMY; MANAGEMENT; LETROZOLE; SURGERY;

D O I：

10.1093/annonc/mdp419

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. Results: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < 2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). Discussion: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.

引用

页码：974 / 982

页数：9

共 50 条

[1] Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer
van de Velde, C.
Seynaeve, C.
Hasenburg, A.
Rea, D.
Vannetzel, J. M.
Paridaens, R.
Markopoulos, C.
Smeets, J.
Nortier, J. W. R.
Jones, S. E.
EJC SUPPLEMENTS, 2009, 7 (03): : 1 - 1
[2] Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries
van Nes, J. G. H.
Seynaeve, C.
Jones, S.
Hasenburg, A.
Rea, D. W.
Vannetzel, J. M.
Dirix, L.
Markopoulos, C.
Kranenbarg, W. M. Meershoek-Klein
van de Velde, C. J. H.
EJC SUPPLEMENTS, 2009, 7 (02): : 301 - 301
[3] Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
J. G. H. van Nes
D. B. Y. Fontein
E. T. M. Hille
D. W. Voskuil
F. E. van Leeuwen
J. C. J. M. de Haes
H. Putter
C. Seynaeve
J. W. R. Nortier
C. J. H. van de Velde
Breast Cancer Research and Treatment, 2012, 134 : 267 - 276
[4] Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ill trial in hormone sensitive postmenopausal early breast cancer
Jones, S. E.
Seynaeve, C.
Hasenburg, A.
Rae, D.
Vannetzel, J-M
Paridaens, R.
Markopoulos, C.
Hozumi, Y.
Putter, H.
Hille, E.
Kieback, D.
Asmar, L.
Smeets, J.
Urbanski, R.
Bartlett, J. M. S.
van de Velde, C. J. H.
CANCER RESEARCH, 2009, 69 (02) : 67S - 67S
[5] Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
van Nes, J. G. H.
Fontein, D. B. Y.
Hille, E. T. M.
Voskuil, D. W.
van Leeuwen, F. E.
de Haes, J. C. J. M.
Putter, H.
Seynaeve, C.
Nortier, J. W. R.
van de Velde, C. J. H.
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 267 - 276
[6] Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: A Dutch TEAM trial analysis
van Nes, Johanna G. H.
Beex, Louk V. A. M.
Seynaeve, Caroline
Putter, Hein
Sramek, Alexandr
Lardenoije, Susanne
Duijm-de Carpentier, Marjolijn
Van Rongen, Inge
Nortier, Johan W. R.
Zonderland, Harmien M.
van de Velde, Cornelis J. H.
ACTA ONCOLOGICA, 2015, 54 (03) : 349 - 360
[7] Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
van Hezewijk, Marjan
Bastiaannet, Esther
Putter, Hein
Scholten, Astrid N.
Liefers, Gerrit-Jan
Rea, Daniel
Hasenburg, Annette
Paridaens, Robert
Hozumi, Yasuo
Markopoulos, Christos
Seynaeve, Caroline
Jones, Stephen E.
Marijnen, Corrie A. M.
van de Velde, Cornelis J. H.
RADIOTHERAPY AND ONCOLOGY, 2013, 108 (02) : 190 - 196
[8] Tamoxifen and exemestane adjuvant multinational (TEAM) trial; findings from the Dutch/belgian subset
Seynaeve, C.
van de Velde, C. J. H.
Maartense, E.
Roumen, R. M. H.
Nortier, J. W. R.
Hille, E. T. M.
van Nes, J. G. H.
Putter, H.
Paridaens, R.
Dirix, L. Y.
EJC SUPPLEMENTS, 2009, 7 (02): : 300 - 300
[9] Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
Schilder, Christina M.
Seynaeve, Caroline
Beex, Louk V.
Boogerd, Willem
Linn, Sabine C.
Gundy, Chad M.
Huizenga, Hilde M.
Nortier, Johan W.
de Velde, Cornelis J. van
van Dam, Frits S.
Schagen, Sanne B.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1294 - 1300
[10] Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Rea, D.
Hasenburg, A.
Seynaeve, C.
Jones, S. E.
Vannetzel, J-M
Paridaens, R.
Markopoulos, C.
Hozumi, Y.
Putter, H.
Hille, E.
Asnar, L.
Urbanski, R.
van de Velde, C. H.
Bartlett, J. M. S.
Smeets, J.
Kieback, D. G.
CANCER RESEARCH, 2009, 69 (24) : 487S - 487S

← 1 2 3 4 5 →